Physician profile
Griffith E Liang
NPI 1891737748
$12,722.97
in general payments reported to CMS, 2019-2025
26 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,146 · 2021: $448 · 2022: $1,142 · 2023: $1,829 · 2024: $6,243 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,943 · Education: $2,622 · Travel and Lodging: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,942.85 |
| Education | $2,621.98 |
| Travel and Lodging | $1,422.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,944.87 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $1,928.30 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,053.40 | 2020-2025 | Nucala, Trelegy Ellipta |
| Covidien LP | $930.51 | 2020 | |
| United Therapeutics Corporation | $742.21 | 2021-2025 | Tyvaso, Remodulin, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.08 | 2020-2025 | Ofev, Stiolto Respimat, Jascayd |
| Electromed, INC. | $566.50 | 2022-2025 | Smartvest |
| Genzyme Corporation | $368.50 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $286.31 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Verona Pharma, INC. | $253.39 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $209.37 | 2021-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $206.28 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $169.86 | 2023-2025 | Winrevair, Zerbaxa |
| Regeneron Healthcare Solutions, INC. | $168.92 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $163.76 | 2024-2025 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $160.78 | 2021-2025 | Xolair |
| Amgen INC. | $148.08 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $136.58 | 2022-2024 | Yupelri |
| Insmed, INC. | $124.03 | 2025 | Arikayce, Brinsupri |
| Philips North America LLC | $100.46 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Vifor Pharma, INC. | $88.07 | 2024-2025 | Zemaira, Veltassa |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Pfizer INC. | $73.42 | 2023 | |
| Advanced Respiratory, INC | $37.62 | 2020 | |
| Viatris Specialty LLC | $34.42 | 2025 | Yupelri |
| Tactile Systems Technology INC | $15.50 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Griffith Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.